Expertise in
1
conditions

Dr. Scott Smith

Anesthesiology
Pinnacle Anesthesia Consultants PLLC
6606 Lyndon B Johnson Fwy Ste 200, 
Dallas, TX 
Expertise in
1
conditions
Pinnacle Anesthesia Consultants PLLC
6606 Lyndon B Johnson Fwy Ste 200, 
Dallas, TX 

Overview

Scott Smith is an Anesthesiologist in Dallas, Texas. Dr. Smith is highly rated in 1 condition, according to our data. His top areas of expertise are Febrile Neutropenia, Classical Hodgkin Lymphoma, T-Cell Lymphoma, Small Lymphocytic Lymphoma (SLL), and Colonoscopy.

His clinical research consists of co-authoring 47 peer reviewed articles and participating in 21 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Anesthesiology

Licenses

Anesthesiology in TX

Hospital Affiliations

Medical City Dallas Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Scott and White Health
  • HMO
  • POS

Locations

Pinnacle Anesthesia Consultants PLLC
6606 Lyndon B Johnson Fwy Ste 200, Dallas, TX 75240
Other Locations
Office
12222 Merit Dr Ste 600, Dallas, TX 75251

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Biological, Procedure
Study Drugs: Bendamustine Hydrochloride, Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Obinutuzumab, Prednisone, Umbralisib, Vincristine Sulfate
Study Phase: Phase 2
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
Enrollment Status: Suspended
Publish Date: April 07, 2026
Intervention Type: Biological, Drug, Procedure, Other
Study Drugs: Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab
Study Phase: Phase 3
An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma
An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma
Enrollment Status: Completed
Publish Date: February 18, 2026
Intervention Type: Drug
Study Drugs: Zanubrutinib, Obinutuzumab
Study Phase: Phase 2
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease
Enrollment Status: Active_not_recruiting
Publish Date: December 18, 2025
Intervention Type: Drug, Other
Study Drugs: Bosutinib, Dasatinib, Nilotinib, Nilotinib Hydrochloride Monohydrate, Ruxolitinib, Ruxolitinib Phosphate
Study Phase: Phase 2
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Enrollment Status: Terminated
Publish Date: August 28, 2025
Intervention Type: Drug
Study Drugs: Brentuximab, Doxorubicin, Vinblastine, Dacarbazine, Nivolumab, Filgrastim
Study Phase: Phase 2
A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)
A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)
Enrollment Status: Completed
Publish Date: July 11, 2025
Intervention Type: Drug
Study Drug: Parsaclisib
Study Phase: Phase 2
Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
Enrollment Status: Terminated
Publish Date: July 10, 2024
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

47 Total Publications

Antigen-specific memory NK cell responses against HIV and influenza use the NKG2/HLA-E axis.
Antigen-specific memory NK cell responses against HIV and influenza use the NKG2/HLA-E axis.
Journal: Science immunology
Published: December 08, 2023
Similar Doctors
Expertise in
10
conditions
Dr. David L. Mcdonagh
Anesthesiology | Neurology
Expertise in
10
conditions
Dr. David L. Mcdonagh
Anesthesiology | Neurology

UT Southwestern - Neurology

5323 Harry Hines Blvd, 
Dallas, TX 
 (7.9 miles away)
214-648-4775
Languages Spoken:
English
See accepted insurances

David Mcdonagh is a Neurologist and an Anesthesiologist in Dallas, Texas. Dr. Mcdonagh is highly rated in 10 conditions, according to our data. His top areas of expertise are Subarachnoid Hemorrhage, Stroke, Hydrocephalus, Brain Tumor, and Awake Craniotomy.

Expertise in
1
conditions
Dr. Srikanth Givvimani
Anesthesiology
Expertise in
1
conditions
Dr. Srikanth Givvimani
Anesthesiology

Metropolitan Anesthesia Consultants, PLLC

3625 N Hall St, Ste 800, 
Dallas, TX 
 (7.4 miles away)
214-252-3500
Languages Spoken:
English
See accepted insurances

Srikanth Givvimani is an Anesthesiologist in Dallas, Texas. Dr. Givvimani is highly rated in 1 condition, according to our data. His top areas of expertise are Malabsorption, Gallbladder Disease, and Intestinal Cancer.

Expertise in
11
conditions
Dr. Don Enty
Anesthesiology
Expertise in
11
conditions
Dr. Don Enty
Anesthesiology

American Pain & Wellness PA

5400 State Highway 121 Ste 100, 
Colleyville, TX 
 (21.9 miles away)
817-354-8697
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Don Enty is an Anesthesiologist in Colleyville, Texas. Dr. Enty is highly rated in 11 conditions, according to our data. His top areas of expertise are Complex Regional Pain Syndrome, Chronic Pain, Sacroiliac Joint Disease, and Myositis.

Frequently Asked Questions about Dr. Scott Smith

How do I make an appointment with Dr. Scott Smith?

You can book an appointment with Dr. Scott Smith by calling their office at 972-715-5000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Scott Smith a top-rated expert for Febrile Neutropenia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Scott Smith is classified as an Advanced expert for Febrile Neutropenia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Scott Smith specialize in?

While Dr. Scott Smith is a Anesthesiology, they have specific expertise in Febrile Neutropenia, Classical Hodgkin Lymphoma, and T-Cell Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Anesthesiology.

Does Dr. Scott Smith participate in research or clinical trials?

Yes. Dr. Scott Smith has published 47 articles and abstracts on conditions like Febrile Neutropenia. You can view a list of Dr. Scott Smith's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Scott Smith accept my insurance?

Dr. Scott Smith accepts most major insurance plans, including Blue Cross Blue Shield and Friday Health. We recommend calling the office directly at 972-715-5000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Smith's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile